Skip to main content

This Week in Clinical Cancer Research: Jan 13, 2012

Premium

In Clinical Cancer Research this week, a team led by researchers at the National Cancer Institute says polycomb repressor complex-2 could be a novel target for mesothelioma therapy. Polycomb group proteins mediate stem cell pluripotency, and have been implicated in the pathogenesis of several cancers, the authors write. The researchers examined PcG protein expression in cultured malignant pleural mesotheliomas, mesothelioma specimens, and normal mesothelial cells, finding that the genes EZH2 and EED — which encode components of polycomb repressor complex-2 — were over-expressed in mesothelioma cell lines compared to normal mesothelial tissue. "EZH2 was over-expressed in approximately 85 percent of MPMs compared with normal pleura, correlating with diminished patient survival," the team says. "Pharmacologic inhibition of PRC-2 expression/activity is a novel strategy for mesothelioma therapy."

Also in Clinical Cancer Research this week, another NCI team assesses the efficacy of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia. The team grew tumor xenografts expressing human CD25 in mice, and then treated the animals with LMB-2 and chemotherapy alone and in combination. They found evidence to suggest that CD25 interacts with LMB-2 in tumors. "Intratumoral sCD25 levels were in the range 21 to 157 (median 54) ng/mL without treatment and 0.95 to 6.1 (median 2.6) ng/mL one day after gemcitabine administration," the team writes. "CD25+ xenografts that were too large to regress with LMB-2 alone were minimally responsive to gemcitabine alone but completely regressed with the combination."

In a paper published online in advance in Clinical Cancer Research this week, a team of researchers in Japan reports on a novel risk classification system for ovarian cancer, based on a 126-gene expression signature. The team analyzed data from 1,054 ovarian cancer patients, and found that its 126-gene expression signature could help predict overall survival. "Through gene ontology and pathway analyses, we identified a significant reduction in expression of immune-response related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients," the authors write. "This risk classification based on the 126-gene expression signature is an accurate predictor of clinical outcome in patients with advanced-stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients."

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.